At our core, Octant is a therapeutics company engineering biology to navigate the biological complexity in drug discovery.
The four components of our platform enable experiments at the massive scale of computational simulations, but with gold-standard real-life experiments in human cells instead. By viewing the biology through this massively parallel experimental lense, we can see problems and solutions that otherwise can’t be seen. Cellular Intelligence unlocks completely new approaches that are more native to how biology actually manifests.
We design, build and test millions of custom cell lines, each precisely engineered to measure the various biochemical activities of drug targets. We engineer these cells with genetic barcodes that measure for us what is happening in the cell.
Nanomole-scale chemical synthesis brings together custom-designed chemical cores with tens of thousands of fragments to enable both exploration and subtle tuning of chemical space to:
Probe the biochemical pathways of human cells
Engineer novel molecules that modulate complex therapeutic profiles
All of this comes together on our massively parallel high throughput drug discovery platform. We iterate on thousands of genetic and chemical inputs to generate millions of biological outputs in human cells.
We use this platform to:
Design gene circuits at unprecedented speeds
Uncover the workings of the biochemical pathways in our bodies
Engineer new therapies to treat multi-factorial diseases
All of the above is enabled, processed, and accelerated by our advanced statistical and machine learning pipelines and tools.
We use the most advanced bioinformatics and software techniques to:
Guide us through complex datasets
Iterate on design decisions
Generate knowledge from our gold-standard experimental data
The mechanistic relationships between genetics, chemistry, and disease are staggeringly complex.
One promising approach to addressing this complexity and solving for “unknowns” is computational models, especially AI.
These approaches conduct thousands of simulations, train them on small amounts of experimental data, and hope that the model recapitulates some of the mechanisms at play. But biology is already the most powerful information processor we know. What if we just scaled actual experiments to outstrip even simulation? That’s what we do at Octant. Our approach, which we call “cellular intelligence” is to instead ask our questions directly within the world we are given by engineering human cells to compute for us.
There are countless rare and common genetic diseases that society is not progressing against, because they’re hard. For example, many major pharmaceutical companies have dropped their neuropsychiatric programs, even though these are some of society’s greatest disease burdens. If they won’t do it, who will?
At Octant, we take next-generation approaches to drug discovery that nobody else is taking. If we don’t do it, who will?
If you are passionate about next-generation drug discovery, we'd love to hear from email@example.com